The European Commission became the first regulatory body to approve preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season with passive immunization.
AstraZeneca and Sanofi’s Beyfortus® (nirsevimab) approval in the European Union was announced on November 4, 2022.
However, the actual availability date in Europe was not disclosed today.
Read More
